Acute and chronic treatments with citalopram lower somatostatin levels in rat brain striatum through different mechanisms

Elena Prosperini, Massimo Rizzi, Fabio Fumagalli, Gianluca Tarizzo, Rosario Samanin, Caterina Bendotti

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

The suggestion that somatostatin is involved in the pathophysiology of obsessive-compulsive disorder and the evidence that selective serotonin reuptake inhibitors show significant antiobsessional effect prompted us to examine the effect of citalopram, a selective and potent serotonin reuptake inhibitor, on the somatostatinergic system in different brain regions of the rat. A single intraperitoneal injection of 10 mg/kg citalopram significantly reduced somatostatin levels in the striatum and nucleus accumbens after 4 but not 1, 8, or 24 h. No changes were found in hippocampus. In addition, we found that the K+-evoked overflow of somatostatin-like immunoreactivity from striatal slices was significantly increased 1 h after a single injection of citalopram and was still higher, although not significantly, 4 h after the drug injection. Levels of preprosomatostatin mRNA were unchanged in striatum and accumbens 1 and 4 h after a single drug administration. In rats treated with citalopram (10 mg/kg i.p.) twice daily for 14 days, the levels of somatostatin and its mRNA were significantly decreased in the striatum but not in other brain regions 24 h after the last dose. No change was found in the basal or K+-evoked overflow of somatostatin-like immunoreactivity at 1, 4, and 24 h after the last drug injection. These results suggest that acute and chronic treatment with citalopram reduces somatostatin levels in striatum by different mechanisms. Whereas a single dose of the drug reduces somatostatin levels by increasing the release of the peptide, repeated drug treatment reduces the biosynthesis of somatostatin.

Original languageEnglish
Pages (from-to)206-213
Number of pages8
JournalJournal of Neurochemistry
Volume69
Issue number1
Publication statusPublished - Jul 1997

Fingerprint

Citalopram
Somatostatin
Rats
Brain
Pharmaceutical Preparations
Serotonin Uptake Inhibitors
Injections
Therapeutics
Drug therapy
Corpus Striatum
Messenger RNA
Obsessive-Compulsive Disorder
Biosynthesis
Nucleus Accumbens
Intraperitoneal Injections
Hippocampus
Peptides

Keywords

  • 5-Hydroxytryptamine uptake inhibitors
  • Basal ganglia
  • Citalopram
  • Obsessive- compulsive disorder
  • Somatostatin

ASJC Scopus subject areas

  • Biochemistry
  • Cellular and Molecular Neuroscience

Cite this

Acute and chronic treatments with citalopram lower somatostatin levels in rat brain striatum through different mechanisms. / Prosperini, Elena; Rizzi, Massimo; Fumagalli, Fabio; Tarizzo, Gianluca; Samanin, Rosario; Bendotti, Caterina.

In: Journal of Neurochemistry, Vol. 69, No. 1, 07.1997, p. 206-213.

Research output: Contribution to journalArticle

Prosperini, Elena ; Rizzi, Massimo ; Fumagalli, Fabio ; Tarizzo, Gianluca ; Samanin, Rosario ; Bendotti, Caterina. / Acute and chronic treatments with citalopram lower somatostatin levels in rat brain striatum through different mechanisms. In: Journal of Neurochemistry. 1997 ; Vol. 69, No. 1. pp. 206-213.
@article{9de0b0b8f6554109ad1755815b69ccba,
title = "Acute and chronic treatments with citalopram lower somatostatin levels in rat brain striatum through different mechanisms",
abstract = "The suggestion that somatostatin is involved in the pathophysiology of obsessive-compulsive disorder and the evidence that selective serotonin reuptake inhibitors show significant antiobsessional effect prompted us to examine the effect of citalopram, a selective and potent serotonin reuptake inhibitor, on the somatostatinergic system in different brain regions of the rat. A single intraperitoneal injection of 10 mg/kg citalopram significantly reduced somatostatin levels in the striatum and nucleus accumbens after 4 but not 1, 8, or 24 h. No changes were found in hippocampus. In addition, we found that the K+-evoked overflow of somatostatin-like immunoreactivity from striatal slices was significantly increased 1 h after a single injection of citalopram and was still higher, although not significantly, 4 h after the drug injection. Levels of preprosomatostatin mRNA were unchanged in striatum and accumbens 1 and 4 h after a single drug administration. In rats treated with citalopram (10 mg/kg i.p.) twice daily for 14 days, the levels of somatostatin and its mRNA were significantly decreased in the striatum but not in other brain regions 24 h after the last dose. No change was found in the basal or K+-evoked overflow of somatostatin-like immunoreactivity at 1, 4, and 24 h after the last drug injection. These results suggest that acute and chronic treatment with citalopram reduces somatostatin levels in striatum by different mechanisms. Whereas a single dose of the drug reduces somatostatin levels by increasing the release of the peptide, repeated drug treatment reduces the biosynthesis of somatostatin.",
keywords = "5-Hydroxytryptamine uptake inhibitors, Basal ganglia, Citalopram, Obsessive- compulsive disorder, Somatostatin",
author = "Elena Prosperini and Massimo Rizzi and Fabio Fumagalli and Gianluca Tarizzo and Rosario Samanin and Caterina Bendotti",
year = "1997",
month = "7",
language = "English",
volume = "69",
pages = "206--213",
journal = "Journal of Neurochemistry",
issn = "0022-3042",
publisher = "Wiley-Blackwell",
number = "1",

}

TY - JOUR

T1 - Acute and chronic treatments with citalopram lower somatostatin levels in rat brain striatum through different mechanisms

AU - Prosperini, Elena

AU - Rizzi, Massimo

AU - Fumagalli, Fabio

AU - Tarizzo, Gianluca

AU - Samanin, Rosario

AU - Bendotti, Caterina

PY - 1997/7

Y1 - 1997/7

N2 - The suggestion that somatostatin is involved in the pathophysiology of obsessive-compulsive disorder and the evidence that selective serotonin reuptake inhibitors show significant antiobsessional effect prompted us to examine the effect of citalopram, a selective and potent serotonin reuptake inhibitor, on the somatostatinergic system in different brain regions of the rat. A single intraperitoneal injection of 10 mg/kg citalopram significantly reduced somatostatin levels in the striatum and nucleus accumbens after 4 but not 1, 8, or 24 h. No changes were found in hippocampus. In addition, we found that the K+-evoked overflow of somatostatin-like immunoreactivity from striatal slices was significantly increased 1 h after a single injection of citalopram and was still higher, although not significantly, 4 h after the drug injection. Levels of preprosomatostatin mRNA were unchanged in striatum and accumbens 1 and 4 h after a single drug administration. In rats treated with citalopram (10 mg/kg i.p.) twice daily for 14 days, the levels of somatostatin and its mRNA were significantly decreased in the striatum but not in other brain regions 24 h after the last dose. No change was found in the basal or K+-evoked overflow of somatostatin-like immunoreactivity at 1, 4, and 24 h after the last drug injection. These results suggest that acute and chronic treatment with citalopram reduces somatostatin levels in striatum by different mechanisms. Whereas a single dose of the drug reduces somatostatin levels by increasing the release of the peptide, repeated drug treatment reduces the biosynthesis of somatostatin.

AB - The suggestion that somatostatin is involved in the pathophysiology of obsessive-compulsive disorder and the evidence that selective serotonin reuptake inhibitors show significant antiobsessional effect prompted us to examine the effect of citalopram, a selective and potent serotonin reuptake inhibitor, on the somatostatinergic system in different brain regions of the rat. A single intraperitoneal injection of 10 mg/kg citalopram significantly reduced somatostatin levels in the striatum and nucleus accumbens after 4 but not 1, 8, or 24 h. No changes were found in hippocampus. In addition, we found that the K+-evoked overflow of somatostatin-like immunoreactivity from striatal slices was significantly increased 1 h after a single injection of citalopram and was still higher, although not significantly, 4 h after the drug injection. Levels of preprosomatostatin mRNA were unchanged in striatum and accumbens 1 and 4 h after a single drug administration. In rats treated with citalopram (10 mg/kg i.p.) twice daily for 14 days, the levels of somatostatin and its mRNA were significantly decreased in the striatum but not in other brain regions 24 h after the last dose. No change was found in the basal or K+-evoked overflow of somatostatin-like immunoreactivity at 1, 4, and 24 h after the last drug injection. These results suggest that acute and chronic treatment with citalopram reduces somatostatin levels in striatum by different mechanisms. Whereas a single dose of the drug reduces somatostatin levels by increasing the release of the peptide, repeated drug treatment reduces the biosynthesis of somatostatin.

KW - 5-Hydroxytryptamine uptake inhibitors

KW - Basal ganglia

KW - Citalopram

KW - Obsessive- compulsive disorder

KW - Somatostatin

UR - http://www.scopus.com/inward/record.url?scp=0030942750&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030942750&partnerID=8YFLogxK

M3 - Article

VL - 69

SP - 206

EP - 213

JO - Journal of Neurochemistry

JF - Journal of Neurochemistry

SN - 0022-3042

IS - 1

ER -